Compare IPCA Labs with Orchid Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ORCHID PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ORCHID PHARMA 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ORCHID PHARMA IPCA LABS/
ORCHID PHARMA
 
P/E (TTM) x 24.1 -118.4 - View Chart
P/BV x 8.6 34.0 25.4% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   ORCHID PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
ORCHID PHARMA
Sep-13
IPCA LABS/
ORCHID PHARMA
5-Yr Chart
Click to enlarge
High Rs1,042194 537.1%   
Low Rs59035 1,686.0%   
Sales per share (Unadj.) Rs298.6276.5 108.0%  
Earnings per share (Unadj.) Rs35.0-79.2 -44.2%  
Cash flow per share (Unadj.) Rs49.4-43.5 -113.8%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs247.153.9 458.2%  
Shares outstanding (eoy) m126.3570.45 179.3%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.70.4 659.8%   
Avg P/E ratio x23.3-1.4 -1,613.0%  
P/CF ratio (eoy) x16.5-2.6 -626.4%  
Price / Book Value ratio x3.32.1 155.6%  
Dividend payout %8.60-   
Avg Mkt Cap Rs m103,1088,067 1,278.2%   
No. of employees `00013.42.8 480.1%   
Total wages/salary Rs m7,8742,527 311.6%   
Avg. sales/employee Rs Th2,807.06,956.1 40.4%   
Avg. wages/employee Rs Th585.8902.5 64.9%   
Avg. net profit/employee Rs Th329.0-1,993.0 -16.5%   
INCOME DATA
Net Sales Rs m37,73219,477 193.7%  
Other income Rs m577407 141.7%   
Total revenues Rs m38,30919,884 192.7%   
Gross profit Rs m6,9011,103 625.9%  
Depreciation Rs m1,8242,519 72.4%   
Interest Rs m1895,227 3.6%   
Profit before tax Rs m5,465-6,236 -87.6%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m1,042-125 -832.6%   
Profit after tax Rs m4,422-5,580 -79.2%  
Gross profit margin %18.35.7 323.1%  
Effective tax rate %19.12.0 950.1%   
Net profit margin %11.7-28.7 -40.9%  
BALANCE SHEET DATA
Current assets Rs m23,77811,014 215.9%   
Current liabilities Rs m10,97532,060 34.2%   
Net working cap to sales %33.9-108.1 -31.4%  
Current ratio x2.20.3 630.6%  
Inventory Days Days10495 109.4%  
Debtors Days Days6634 196.5%  
Net fixed assets Rs m20,36829,440 69.2%   
Share capital Rs m253705 35.9%   
"Free" reserves Rs m30,9712,043 1,516.3%   
Net worth Rs m31,2243,800 821.7%   
Long term debt Rs m1,4099,018 15.6%   
Total assets Rs m45,50746,510 97.8%  
Interest coverage x30.0-0.2 -15,513.2%   
Debt to equity ratio x02.4 1.9%  
Sales to assets ratio x0.80.4 198.0%   
Return on assets %10.1-0.8 -1,333.1%  
Return on equity %14.2-146.9 -9.6%  
Return on capital %17.3-3.7 -463.9%  
Exports to sales %45.937.9 121.1%   
Imports to sales %16.622.6 73.4%   
Exports (fob) Rs m17,3087,378 234.6%   
Imports (cif) Rs m6,2664,406 142.2%   
Fx inflow Rs m17,3087,513 230.4%   
Fx outflow Rs m6,2665,649 110.9%   
Net fx Rs m11,0421,865 592.2%   
CASH FLOW
From Operations Rs m4,9231,682 292.7%  
From Investments Rs m-1,563-9,860 15.9%  
From Financial Activity Rs m-1,8326,644 -27.6%  
Net Cashflow Rs m1,528-1,535 -99.5%  

Share Holding

Indian Promoters % 45.9 32.3 142.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 4.6 247.8%  
FIIs % 25.3 3.3 766.7%  
ADR/GDR % 0.0 4.6 -  
Free float % 17.4 55.3 31.5%  
Shareholders   36,892 84,811 43.5%  
Pledged promoter(s) holding % 2.1 54.9 3.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   TTK HEALTHCARE  ALEMBIC  WYETH  ELDER PHARMA  BIOCON   

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

TRAI Data for February, Siemens March Quarter Performance, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed selling pressure on Wednesday and ended lower.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


May 12, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS